These findings represent the first direct evidence of a critical role for CCR2-driven inflammatory MO recruitment in DMD pathogenesis and additionally identify CCR2 as an important modulator of disease severity, thus indicating its potential to serve as a new therapeutic target in DMD. This evidence concerns the gene CCR2 and Duchenne muscular dystrophy.